- Home
- CFFI vs PLX Comparison
CFFI vs PLX Comparison
Compare CFFI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFFI
- PLX
- Stock Information
- Founded
- CFFI 1927
- PLX 1993
- Country
- CFFI United States
- PLX United States
- Employees
- CFFI N/A
- PLX N/A
- Industry
- CFFI Major Banks
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CFFI Finance
- PLX Health Care
- Exchange
- CFFI Nasdaq
- PLX Nasdaq
- Market Cap
- CFFI 218.0M
- PLX 204.9M
- IPO Year
- CFFI 1998
- PLX 1998
- Fundamental
- Price
- CFFI $68.86
- PLX $1.74
- Analyst Decision
- CFFI
- PLX Strong Buy
- Analyst Count
- CFFI 0
- PLX 1
- Target Price
- CFFI N/A
- PLX $15.00
- AVG Volume (30 Days)
- CFFI 3.7K
- PLX 640.8K
- Earning Date
- CFFI 10-23-2025
- PLX 11-13-2025
- Dividend Yield
- CFFI 2.65%
- PLX N/A
- EPS Growth
- CFFI 43.03
- PLX N/A
- EPS
- CFFI 8.09
- PLX 0.07
- Revenue
- CFFI $125,432,000.00
- PLX $61,840,000.00
- Revenue This Year
- CFFI N/A
- PLX $14.53
- Revenue Next Year
- CFFI N/A
- PLX $75.77
- P/E Ratio
- CFFI $8.43
- PLX $25.19
- Revenue Growth
- CFFI 9.28
- PLX 35.41
- 52 Week Low
- CFFI $53.14
- PLX $1.32
- 52 Week High
- CFFI $89.90
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CFFI 50.06
- PLX 30.70
- Support Level
- CFFI $66.48
- PLX $1.70
- Resistance Level
- CFFI $71.25
- PLX $1.93
- Average True Range (ATR)
- CFFI 1.19
- PLX 0.14
- MACD
- CFFI -0.18
- PLX -0.06
- Stochastic Oscillator
- CFFI 49.79
- PLX 2.82
About CFFI C&F Financial Corporation
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.